ReviewCureus2025
Pooled Incidence of Heparin-Induced Thrombocytopenia and Anti-Platelet Factor 4 Antibody Formation Among Adults: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated drug reaction. Patients with HIT show thrombocytopenia and increased thrombotic risk. Unfractionated heparin (UFH) is more immunogenic compared to low-molecular-weight heparin (LMWH), but estimates vary across clinical settings. The study aimed to determine the pooled incidence of thrombocytopenia and anti-platelet factor (PF)-4 antibody formation among adults exposed to UFH and LMWH. We systematically searched electronic databases, including PubMed, Cochrane CENTRAL, Embase (via Cochrane), the International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov, for studies published from 2010 to 2025. Eligible studies reported clinical HIT incidence or anti-PF4/heparin antibody formation in adults receiving UFH or LMWH. Two reviewers independently performed screening and data extraction. Bias risk was assessed using the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I). Random-effects models pooled risk ratios (RRs) comparing UFH with LMWH. Twelve studies comprising 139,744 adults were included. Six studies reporting clinical HIT showed more risk with UFH (RR 3.4; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.